AMLX rises as Avexitide nears 2026-end filing with Phase III study win
- Posted on August 19, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
AMLX rises as Avexitide nears 2026-end filing with Phase III study win
Shares of Amylyx Pharmaceuticals AMLX surged 63.8% yesterday after it announced positive top-line data from the phase III LUCIDITY study. This study evaluated its lead candidate, avexitide, a GLP-1 receptor antagonist, in participants with post-bariatric hypoglycemia (“PBH”), following Roux-en-Y gastric bypass surgery. Year to date, shares of Amylyx have rallied 190.7% against the industry’s decline of 0.8%. Image Source: Zacks Investment...
-copy.jpeg?trim=78,0,79,0&width=1200&height=800&crop=1200:800)